Citizens downgraded enGene (ENGN) to Market Perform from Outperform without a price target The company’s updated results from the pivotal LEGEND study “worsened significantly,” the analyst tells investors in a research note. The firm now sees enGene’s competitive nature in non-muscle invasive bladder cancer as unfavorable.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene downgraded to Equal Weight from Overweight at Wells Fargo
- enGene downgraded to Equal Weight from Overweight at Morgan Stanley
- enGene downgraded to Neutral from Buy at Guggenheim
- enGene announces updated interim results from LEGEND cohort
- enGene Releases Mixed Interim Data from LEGEND Phase 2 Trial